The COVID-19 working group of the National Technical Advisor (NTAGI) will review the new corona vaccine 'Covovax' developed by the Serum Institute of India (SII). This vaccine is designed for children and adults specifically. And the review meeting will be held on April 1. The NTAGI set up for Immunization has a three-tier system to decide on a vaccine. This working group is of the first level review. A second-level Standing Technical Sub-Committee (STSC) will review and discuss the safety and effectiveness of the vaccine data after the working group looks at the safety and effectiveness of the vaccine data. Thereafter, STSC will give its decision to the third group to make the final decision. Booster Dose Is Not For Everyone In the meeting to be held on Friday, NTAGI will not discu...
Read MoreTag: NOVAVAX
COVOVAX Vaccine By Serum Institute of India Gets Emergency Approval From WHO
Covovax Vaccine by the Serum Institute of India [SII] gets the approval from the WHO for emergency use. Under the license from Novavax, Covovax will be produced in India by the SII. It is a part of COVAX, a worldwide initiative aimed at providing, equitable access to COVID-19 vaccines. Moving ahead in this direction the WHO issuing emergency use listing of the Covovax is a step in expanding the basket of jabs validated by the global health body against Corona. As a result of this step by the WHO Covovax becomes the 9th vaccine to be listed. Meanwhile Adar Poonawalla tweets, "This is yet another milestone in our fight against COVID-19, showing excellent safety and efficacy. Thank you all for a great collaboration." Indeed its a great news among the rising cases of Omicron variant across...
Read More
